Explore Q1 2025's biotech stock moves, from CervoMed's 300% surge to Septerna's struggles. Click for my review of the quarter ...
The new study in animal models will investigate whether “initiated” cells, harboring a mutant RAS oncogene, can be eliminated with LB-100. If successful, LB-100 could have a significant role in the ...
Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian ...
Traditional defensive stocks Johnson & Johnson, United Health, and Procter & Gamble are all up and helping to keep the S&P ...
CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...
Bismuth prices in Europe have surged to all-time highs as China's export controls squeeze supplies of the mineral used in atomic research, cosmetics and pharmaceuticals, according to traders and ...
PASADENA, CALIF., March 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage ...
14d
Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), ...
Minister of Public Health, Dr. Rakan Nassereddine, and Minister of Labor, Dr. Mohammad Haidar, on Tuesday held a joint meeting at the Ministry of Health, bringing together Dir ...
Reports FY24 revenue $9.7M, consensus $9.34M. “Following the highly encouraging 16-week extension results from our Phase 2b RewinD-LB trial, we ...
The Trump administration claims gutting federal agencies will save money, but cutting the IRS means the government collects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback